237 related articles for article (PubMed ID: 27498059)
21. CD138 (syndecan-1) expression in bone-forming tumors.
Nunez AL; Siegal GP; Reddy VV; Wei S
Am J Clin Pathol; 2012 Mar; 137(3):423-8. PubMed ID: 22338054
[TBL] [Abstract][Full Text] [Related]
22. Wnt signaling in osteosarcoma.
Lin CH; Ji T; Chen CF; Hoang BH
Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
[TBL] [Abstract][Full Text] [Related]
23. Sclerostin expression in bone tumours and tumour-like lesions.
Inagaki Y; Hookway ES; Kashima TG; Munemoto M; Tanaka Y; Hassan AB; Oppermann U; Athanasou NA
Histopathology; 2016 Sep; 69(3):470-8. PubMed ID: 26896083
[TBL] [Abstract][Full Text] [Related]
24. Heparin affects human bone marrow stromal cell fate: Promoting osteogenic and reducing adipogenic differentiation and conversion.
Simann M; Schneider V; Le Blanc S; Dotterweich J; Zehe V; Krug M; Jakob F; Schilling T; Schütze N
Bone; 2015 Sep; 78():102-13. PubMed ID: 25959412
[TBL] [Abstract][Full Text] [Related]
25. Dihydromyricetin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro partially via the activation of Wnt/β-catenin signaling pathway.
Zhang W; Wang S; Yin H; Chen E; Xue D; Zheng Q; Gao X; Pan Z
Fundam Clin Pharmacol; 2016 Dec; 30(6):596-606. PubMed ID: 27469984
[TBL] [Abstract][Full Text] [Related]
26. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration.
Wang FS; Wu RW; Lain WS; Tsai TC; Chen YS; Sun YC; Ke HJ; Li JC; Hwang J; Ko JY
Bone; 2018 Jul; 112():24-34. PubMed ID: 29653294
[TBL] [Abstract][Full Text] [Related]
27. Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: an immunohistochemical study.
Gouin F; Moreau A; Couillaud S; Guicheux J; Passuti N; Godard A; Heymann D
J Orthop Res; 1999 Mar; 17(2):301-5. PubMed ID: 10221849
[TBL] [Abstract][Full Text] [Related]
28. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
29. SOST Inhibits Prostate Cancer Invasion.
Hudson BD; Hum NR; Thomas CB; Kohlgruber A; Sebastian A; Collette NM; Coleman MA; Christiansen BA; Loots GG
PLoS One; 2015; 10(11):e0142058. PubMed ID: 26545120
[TBL] [Abstract][Full Text] [Related]
30. Bone-Forming Tumors.
Zhang Y; Rosenberg AE
Surg Pathol Clin; 2017 Sep; 10(3):513-535. PubMed ID: 28797500
[TBL] [Abstract][Full Text] [Related]
31. Wnt-β-catenin signaling pathway inhibition by sclerostin may protect against degradation in healthy but not osteoarthritic cartilage.
Wu J; Ma L; Wu L; Jin Q
Mol Med Rep; 2017 May; 15(5):2423-2432. PubMed ID: 28259981
[TBL] [Abstract][Full Text] [Related]
32. Expression of bone morphogenetic proteins and receptors in sarcomas.
Guo W; Gorlick R; Ladanyi M; Meyers PA; Huvos AG; Bertino JR; Healey JH
Clin Orthop Relat Res; 1999 Aug; (365):175-83. PubMed ID: 10627702
[TBL] [Abstract][Full Text] [Related]
33. SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/β-catenin signaling pathway.
Wu T; Wang LN; Tang DR; Sun FY
Gene Ther; 2017 Jul; 24(7):399-407. PubMed ID: 28485721
[TBL] [Abstract][Full Text] [Related]
34. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
35. Expression of connective tissue growth factor in cartilaginous tumors.
Shakunaga T; Ozaki T; Ohara N; Asaumi K; Doi T; Nishida K; Kawai A; Nakanishi T; Takigawa M; Inoue H
Cancer; 2000 Oct; 89(7):1466-73. PubMed ID: 11013359
[TBL] [Abstract][Full Text] [Related]
36. Co-expression of DKK-1 and Sclerostin in Subchondral Bone of the Proximal Femoral Heads from Osteoarthritic Hips.
Zarei A; Hulley PA; Sabokbar A; Javaid MK
Calcif Tissue Int; 2017 Jun; 100(6):609-618. PubMed ID: 28275825
[TBL] [Abstract][Full Text] [Related]
37. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types.
Vega OA; Lucero CMJ; Araya HF; Jerez S; Tapia JC; Antonelli M; Salazar-Onfray F; Las Heras F; Thaler R; Riester SM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2017 Nov; 118(11):3662-3674. PubMed ID: 28370561
[TBL] [Abstract][Full Text] [Related]
38. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
[TBL] [Abstract][Full Text] [Related]
39. RUNX2 expression in developing human bones and various bone tumors.
Sugawara M; Kato N; Tsuchiya T; Motoyama T
Pathol Int; 2011 Oct; 61(10):565-71. PubMed ID: 21951664
[TBL] [Abstract][Full Text] [Related]
40. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.
Chan BY; Fuller ES; Russell AK; Smith SM; Smith MM; Jackson MT; Cake MA; Read RA; Bateman JF; Sambrook PN; Little CB
Osteoarthritis Cartilage; 2011 Jul; 19(7):874-85. PubMed ID: 21619935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
